Get started

Healthcare

CVS moment of truth is comingCVS has been headed toward the top of its parallel channel. It's currently overbought, so its first test of the channel top may get rejected. However, expect a breakout soon after. CVS is my favorite investment thesis in the entire market right now. The company is opening 1500 HealthHub stores by the end of 2021 and is also completing a merger with Aetna. Its earnings are expected to grow, and the stock is absurdly undervalued. Fair value based on forward P/E for 2021 is something like $95 per share. Even based on this year's P/E, it should be at least $79. (I base these numbers on the Zack's "Price and Consensus" chart, which is one of my favorite tools for fundamental analysis. We'll do an educational episode on this on the "Wall Street Petting Zoo" Youtube channel next week.)
NYSE:CVSLong
by ChristopherCarrollSmith
Harrow may bounce on lawsuit newsBack in May, a jury ruled in Harrow Health's favor in a lawsuit that Allergan filed against Harrow for intellectual property infringement. Allergan has been appealing the ruling, but today the two companies jointly filed an 8k form indicating that they had jointly dismissed all pending appeals and exchanged no money. In other words, Harrow got off scot-free and will no longer incur legal fees related to the case. This is great news, so it's surprising that the stock is down, especially when the market as a whole is up. Perhaps Harrow will get a boost if some news agencies pick up the story. In the meantime, Harrow is approaching support at about $5. I picked up a few shares at $5.25 and will look to buy more at $5. Harrow Health has a 9.4/10 Equity StarMine Summary Score and is rated undervalued (73/100) by S&P Capital IQ.
NASDAQ:HROWLong
by ChristopherCarrollSmith
$VIVE Classic "Cursed After Reversed" Or Can It ReVIVE Itself?VIVE seems like it can't get out of its own way. Great gap up in the morning but yet again, another red close. Even after reversing, shares are back at penny stock levels. So is it doomed to repeat history or can it find a new bottom? I don't know if anyone really knows for sure just yet. "Viveve’s stock price had a terrible September, dropping more than 57%. However, its start to October is looked promising at the start. The healthcare penny stock gapped up over 25% during premarket hours on October 1st. In addition, the penny stock has already tripled its average trading volume. But as you see, VIVE stock has pulled back considerably from those premarket highs."* *Quote Source: 5 Money Making Penny Stocks To Watch This Week Most Recent News: Viveve Raises $6.76 million Through Completion of At-The-Market Equity Financing ENGLEWOOD, CO / ACCESSWIRE / October 1, 2019 / Viveve Medical, Inc. (VIVE), a medical technology company focused on women's intimate health, today announced the completion of its at-the-market (ATM) offering of $6.76 million of shares of its common stock with Ladenburg Thalmann & Co. Inc. as the sales agent. The company sold 1,004,171 shares at a weighted average price of $6.73 per share (adjusting for a reverse stock split of Viveve common stock effected September 18, 2019) resulting in net proceeds of approximately $6.56 million to the company after deduction of sales commissions. As of September 30, 2019, the company had 1,469,589 shares outstanding. About VIVE Viveve Medical, Inc. is a medical technology company focused on women's intimate health. Viveve is committed to advancing new solutions to improve women's overall well-being and quality of life. The internationally patented Viveve® System incorporates cryogen-cooled monopolar radiofrequency (CMRF) technology to uniformly deliver volumetric heating while gently cooling surface tissue to generate neocollagenesis in a single in-office session. News Source: finance.yahoo.com
V
by PennyStocks101
1
Why Is KSHB Going Up While Most Pot Stocks Are Getting Slammed?KSHB has been one of just a fine few pot stock related names that has actually gone up. So what's the deal? The company’s stock price struggled throughout September, decreasing 60% on a massive drop during trading hours on September 26th. This was due to the company announcing a direct offering for shares at $1.75 per. This cannabis company is comprised of several industry-leading companies. This includes one of the largest producers of vaporizer products and packaging, Kush Supply Co. Furthermore, it owns Kush Energy which provides hydrocarbon gases and solvents to the cannabis sector. "The direct offering was valued at $30.2 million and is expected to close relatively soon. Investors must have found this offering promising because today, on October 1st, the marijuana stock is up 11%. Could this lead to a strong and promising October for investors after that rough September?"* *Quote Source: 5 Penny Stocks To Watch This Week Stock: KSHB
K
by PennyStocks101
A healthcare sector play without the political riskI posted the other day about how the healthcare sector would be a good defensive play in October but for the political risk faced by health insurers and pharmaceutical companies. Well, here's a company with great financials and none (or at least less) of that political risk. SMED is a medical waste disposal company, and its services would still be in demand even if the US passed a universal healthcare law. SMED has an 8.8 Equity StarMine Summary Score and is rated "Undervalued" by the fundamental analysts at S&P Capital IQ. It's a little high in its RSI channel right now, but it still seems to be uptrending. I expect it will soon retest its recent highs at 4.46-4.48, and if it pushes above that level then it could get a nice breakout. SMED utterly destroyed analyst expectations on its last earnings report and has plenty of room to run.
SLong
by ChristopherCarrollSmith
UNH insider sales flash a warning sign ahead of earningsUnitedHealth Group has had an incredibly strong showing this year, and right now it's priced pretty attractively at oversold level on the hourly chart. On its daily chart it's at RSI 38, nearing oversold (RSI 30) but not quite there yet. It also hasn't yet tested its August low of 220.78 or its one-year lows of 208.07 and 216.84. I suspect we'll get a bounce tomorrow from the hourly oversold level, then fall some more to the 216-220 range. At that point we should be about oversold on the daily chart and should bounce into earnings on October 15. The average analyst price target on UNH is about 299, implying about 33% upside from the current price. Analyst estimates of UNH earnings have held steady for the past month at 3.77, significantly better than 3.41 the same quarter last year. UNH has an 8.7/10 Equity Starmine Summary Score rating. So most signs are bullish. However, company director Richard Burke sold 10,000 shares last week. Other directors also recently sold thousands of shares. All this insider selling doesn't inspire confidence for good earnings this quarter. On that basis alone, I don't think I'd hold this for anything more than a pre-earnings bounce. On the other hand, insider sellers may be responding to political risk rather than to the company's financials. The healthcare sector is expected to report good earnings this quarter, which could make it attractive as a defensive play in an earnings recession. Healthcare is a defensive sector that usually does well when the rest of the market is down. Right now healthcare stocks are cheap, which makes them even more attractive. However, with Elizabeth Warren leading the Democratic pack, UNH's share price may continue its breakdown. Health insurance and pharmaceutical companies are at particular risk from Warren's "Medicare for All" plan, and you may be able to chart healthcare stocks' performance from now until the election as a function of Warren's popularity in the polls.
NYSE:UNH
by ChristopherCarrollSmith
SAVA - Above MA's Possible 15% TargetCassava Sciences, Inc. engages in the development of novel drugs. It focuses on developing product candidates intended for the treatment of Alzheimer's disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier and Barry M. Sherman in May 1998 and is headquartered in Austin, TX. SHORT INTEREST 1.64M 08/30/19 P/E Current -2.07 P/E Ratio (with extraordinary items) -5.00 Average Recommendation: BUY Average Target Price: 3.00
NASDAQ:SAVALong
by DEXWireNews
CVS attempting rising wedge breakoutCVS has been testing the upper trend line of its rising wedge, which it has breached a couple times in the last two days. The last three days have also seen heavy call option buying activity. CVS has a very bullish 9.4/10 Equity StarMine rating, and it's rated as extremely undervalued by S&P Capital IQ. Investors are betting, in part, that CVS will benefit from the bankruptcy of Fred's, a major competitor. CVS is also now going to be selling a CBD (cannabis) product from SocialCBD. Plus, CVS has big plans to open 50 HealthHUB stores, low-cost clinics that will leverage artificial intelligence as a diagnostic tool. This could help disrupt the cost bubble in the healthcare industry. I don't know that the rising wedge will necessarily break today, but I do think that CVS should see continued strength in the coming year. This is a good long-term buy and hold.
NYSE:CVSLong
by ChristopherCarrollSmith
Gonna Need A Bigger Boat CYHThe biotech sector is known for generating some of the most volatile names around and for good reason. When it comes to biotech and healthcare stocks, innovation is the focus. " Healthcare penny stock Community Health Systems Inc. ( CYH ) is a healthcare company that buys and runs acute care hospitals in the US. The company operates an impressive 103 hospitals across 18 states, holding 17,000 beds. Ever since August 28th, CYH stock has been thriving. It is up over 82% since the 28th going from $1.82 to $3.48." But between the divestiture of assets and this insider buying well below the current share price, what comes next? What catalyst can we look toward now? "From August 27th to August 29th, more than $2 million was spent between Wayne Smith and Benjamin Fordham to pick up more than 1 million shares. The majority of these shares were bought by Smith at an average price between $1.84 and $2.18" 3 Penny Stocks On Robinhood To Watch This Week pennystocks.com
NYSE:CYH
by PennyStocks101
J&J vs opioids (Johnson is winning)Fundamental analysis In one of the first state opioid cases, an Oklahoma judge ruled against Johnson & Johnson, awarding the state $572 million, well below the over $17 billion the state was seeking in damages. Meaning... out of the 17 billion, they lost only 3.36%, and they expect to appeal the case, probably lowering this amount. Technical analysis On a technical analysis, I still think the risk reward ratio is too small to enter a position now. But technicals are good (not great). So I am keeping this on my watchlist.
NYSE:JNJ
by dorfmanmaster
Bullish SharkLeap is looking to make another leap. Harmonic shark patterns leave more room for volatility trades and make for high reward scenario's when traded correctly. As of today (09-04-2019), 84,220 of the 261,828 shares traded where short. This is equivalent to a sizable 32.17% short percent. The technical's are now aligning with some key dates with a potential short squeeze on its way (assuming good data). $LPTX is trading at the lower end of the long-term trading range. Bullish harmonic shark pattern, look for profit taking and/ or chances to add at the 382 and 50 retracement levels to ride up to the top of the range. Not only does this trade have massive upside potential for a swing trade, it is also showing confluence with Fibonacci time-cycles, fib-retracement and trend. Tip of the day: Learning how to be disciplined is vital to trading volatility. Follow our trading team for ideas on how to stay more disciplined in biotech. Disclosure: I have no position in LPTX. I may buy or sell in the next 72 hours. This is not a note to but or sell. Please do your homework before investing.
NASDAQ:LPTXLong
by follow_the_money